{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:30:29Z","timestamp":1771306229612,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95713-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:15:02Z","timestamp":1751393702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pretreatment PET dissemination features as biomarkers for survival outcomes in melanoma patients treated with immune-checkpoint inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Hanna","family":"Saadani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else A.","family":"Aalbersberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutamba T.","family":"Kayembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto S.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel P.M.","family":"Stokkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"95713_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158, 495\u2013503 (2022).","journal-title":"JAMA Dermatol."},{"key":"95713_CR2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma. Lancet 392, 971\u2013984 (2018).","journal-title":"Lancet"},{"key":"95713_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"95713_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok, J. D. et al. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11\u201322 (2025).","journal-title":"N. Engl. J. Med."},{"key":"95713_CR5","doi-asserted-by":"publisher","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018). https:\/\/doi.org\/10.1126\/science.aar4060.","DOI":"10.1126\/science.aar4060"},{"key":"95713_CR6","first-page":"514","volume":"42","author":"C Lee Ventola","year":"2017","unstructured":"Lee Ventola, C. Cancer immunotherapy, part 3: challenges and future trends. P T. 42, 514\u2013521 (2017).","journal-title":"P T"},{"key":"95713_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/biomedicines11030749","volume":"11","author":"T Mesti","year":"2023","unstructured":"Mesti, T., Gra\u0161i\u010d Kuhar, C. & Ocvirk, J. Biomarkers for outcome in metastatic melanoma in first line treatment with immune checkpoint inhibitors. Biomedicines 11, 749 (2023).","journal-title":"Biomedicines"},{"key":"95713_CR8","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide, B. et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin. Cancer Res. 22, 5487\u20135496 (2016).","journal-title":"Clin. Cancer Res."},{"key":"95713_CR9","unstructured":"Reuben, A. et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. npj Genomic Med. 2, 1\u201311 (2017)."},{"key":"95713_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa, T. M., Paskal, W. & W\u0142odarski, P. K. Intratumor and intertumor heterogeneity in melanoma. Transl. Oncol. 10, 956 (2017).","journal-title":"Transl. Oncol."},{"key":"95713_CR11","doi-asserted-by":"publisher","unstructured":"Fine, G. C. et al. PET-CT in clinical adult oncology\u2014VI. Primary cutaneous cancer, sarcomas and neuroendocrine tumors. Cancers 14, 2835 (2022). https:\/\/doi.org\/10.3390\/cancers14122835.","DOI":"10.3390\/cancers14122835"},{"key":"95713_CR12","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"RD Seban","year":"2020","unstructured":"Seban, R. D. et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur. J. Nucl. Med. Mol. Imaging. 47, 2301\u20132312 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR13","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"RD Seban","year":"2019","unstructured":"Seban, R. D. et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur. J. Nucl. Med. Mol. Imaging. 46, 2298\u20132310 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","volume":"48","author":"N Ayati","year":"2021","unstructured":"Ayati, N. et al. The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 48, 428\u2013448 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrclinonc.2016.162","volume":"14","author":"JPB O\u2019Connor","year":"2017","unstructured":"O\u2019Connor, J. P. B. et al. Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol. 14, 169\u2013186 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"95713_CR16","doi-asserted-by":"crossref","unstructured":"Kinahan, P. E. et al. The QIBA profile for FDG PET\/CT as an imaging biomarker measuring response to cancer therapy. Radiology 294, 647\u2013657 (2020).","DOI":"10.1148\/radiol.2019191882"},{"key":"95713_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0212223","volume":"14","author":"E Pfaehler","year":"2019","unstructured":"Pfaehler, E., Zwanenburg, A., de Jong, J. R. & Boellaard, R. RACAT: an open source and easy to use radiomics calculator tool. PLoS One. 14, 1\u201326 (2019).","journal-title":"PLoS One"},{"key":"95713_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau, A. S. et al. 18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J. Nucl. Med. 61, 40\u201345 (2020).","journal-title":"J. Nucl. Med."},{"key":"95713_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2967\/jnumed.118.209544","volume":"60","author":"BF Kurland","year":"2019","unstructured":"Kurland, B. F. et al. Test\u2013retest reproducibility of 18F-FDG PET\/CT uptake in cancer patients within a qualified and calibrated local network. J. Nucl. Med. 60, 608\u2013614 (2019).","journal-title":"J. Nucl. Med."},{"key":"95713_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s00259-018-4211-0","volume":"46","author":"K Ito","year":"2019","unstructured":"Ito, K. et al. Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in melanoma patients treated with ipilimumab therapy. Eur. J. Nucl. Med. Mol. Imaging. 46, 930\u2013939 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR21","doi-asserted-by":"publisher","unstructured":"Klemen, N. D. et al. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J. Immunother. Cancer 8, e000341 (2020). https:\/\/doi.org\/10.1136\/jitc-2019-000341.","DOI":"10.1136\/jitc-2019-000341"},{"key":"95713_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mdz050","volume":"30","author":"D Schadendorf","year":"2019","unstructured":"Schadendorf, D., Livingstone, E. & Zimmer, L. Treatment in metastatic melanoma-time to re-think. Ann. Oncol. 30, 501\u2013503 (2019).","journal-title":"Ann. Oncol."},{"key":"95713_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard, R. et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging. 42, 328\u2013354 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink, J. J. et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging. 49, 932\u2013942 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR25","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1007\/s00259-020-05068-3","volume":"48","author":"J van Sluis","year":"2021","unstructured":"van Sluis, J. et al. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. Eur. J. Nucl. Med. Mol. Imaging. 48, 1498\u20131510 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell","year":"1996","unstructured":"Harrell, F. E., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361\u2013387 (1996).","journal-title":"Stat. Med."},{"key":"95713_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CMR.0000000000000520","volume":"29","author":"F Petrelli","year":"2019","unstructured":"Petrelli, F. et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: A systematic review and meta-analysis. Melanoma Res. 29, 1\u201312 (2019).","journal-title":"Melanoma Res."},{"key":"95713_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40257-017-0325-6","volume":"19","author":"EA Rozeman","year":"2018","unstructured":"Rozeman, E. A., Dekker, T. J. A., Haanen, J. B. A. G. & Blank, C. U. Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am. J. Clin. Dermatol. 19, 303\u2013317 (2018).","journal-title":"Am. J. Clin. Dermatol."},{"key":"95713_CR29","first-page":"658","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. The cancer immunogram. Sci. (1979). 352, 658\u2013660 (2016).","journal-title":"Sci. (1979)"},{"key":"95713_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","volume":"21","author":"D Kuk","year":"2016","unstructured":"Kuk, D. et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist 21, 848 (2016).","journal-title":"Oncologist"},{"key":"95713_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. Response criteria in solid tumors. J. Nucl. Med. 50, 1\u201350 (2009).","journal-title":"J. Nucl. Med."},{"key":"95713_CR32","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","volume":"47","author":"R Nakamoto","year":"2020","unstructured":"Nakamoto, R. et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur. J. Nucl. Med. Mol. Imaging. 47, 2787\u20132795 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-020-00313-2","volume":"20","author":"A Wong","year":"2020","unstructured":"Wong, A. et al. 18F-FDG PET\/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 20, 1\u201312 (2020).","journal-title":"Cancer Imaging"},{"key":"95713_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2214\/AJR.18.19796","volume":"212","author":"Y Sanli","year":"2019","unstructured":"Sanli, Y., Leake, J., Odu, A., Xi, Y. & Subramaniam, R. M. Tumor heterogeneity on FDG PET\/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma. Am. J. Roentgenol. 212, 1318\u20131326 (2019).","journal-title":"Am. J. Roentgenol."},{"key":"95713_CR35","doi-asserted-by":"crossref","unstructured":"Iravani, A. et al. FDG PET\/CT prognostic markers in patients with advanced melanoma treated with ipilimumab and nivolumab. Radiology 307, e221180 (2023).","DOI":"10.1148\/radiol.221180"},{"key":"95713_CR36","doi-asserted-by":"crossref","unstructured":"Huang, A. C. & Zappasodi, R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23, 660\u2013670 (2022).","DOI":"10.1038\/s41590-022-01141-1"},{"key":"95713_CR37","doi-asserted-by":"publisher","unstructured":"Jacquelot, N., Duong, C. P. M., Belz, G. T. & Zitvogel, L. Targeting chemokines and chemokine receptors in melanoma and other cancers. Front. Immunol. 9, 2480 (2018). https:\/\/doi.org\/10.3389\/fimmu.2018.02480.","DOI":"10.3389\/fimmu.2018.02480"},{"key":"95713_CR38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CMR.0000000000000346","volume":"27","author":"M Mendt","year":"2017","unstructured":"Mendt, M. & Cardier, J. E. Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis. Melanoma Res. 27, 300\u2013307 (2017).","journal-title":"Melanoma Res."},{"key":"95713_CR39","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1158\/1078-0432.CCR-05-1940","volume":"12","author":"S Scala","year":"2006","unstructured":"Scala, S. et al. Human melanoma metastases express functional CXCR4. Clin. Cancer Res. 12, 2427\u20132433 (2006).","journal-title":"Clin. Cancer Res."},{"key":"95713_CR40","doi-asserted-by":"publisher","unstructured":"Murakami, T., Cardones, A. R. & Hwang, S. T. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 36, 71\u201378 (2004). https:\/\/doi.org\/10.1016\/j.jdermsci.2004.03.002.","DOI":"10.1016\/j.jdermsci.2004.03.002"},{"key":"95713_CR41","first-page":"7328","volume":"62","author":"T Murakami","year":"2002","unstructured":"Murakami, T. et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62, 7328\u20137334 (2002).","journal-title":"Cancer Res."},{"key":"95713_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ijc.21269","volume":"117","author":"MI Longo-Imedio","year":"2005","unstructured":"Longo-Imedio, M. I., Longo, N., Trevi\u00f1o, I. & L\u00e1zaro, P. S\u00e1nchez-Mateos, P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int. J. Cancer. 117, 861\u2013865 (2005).","journal-title":"Int. J. Cancer"},{"key":"95713_CR43","doi-asserted-by":"crossref","unstructured":"Scala, S. et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 11, 1835\u20131841 (2005).","DOI":"10.1158\/1078-0432.CCR-04-1887"},{"key":"95713_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","volume":"32","author":"AS Cottereau","year":"2021","unstructured":"Cottereau, A. S. et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020. Ann. Oncol. 32, 404\u2013411 (2021).","journal-title":"Ann. Oncol."},{"key":"95713_CR45","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1007\/s00259-022-05916-4","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink, J. J. et al. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET\/CT radiomics features. Eur. J. Nucl. Med. Mol. Imaging. 49(13), 4642\u20134651 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"95713_CR46","doi-asserted-by":"publisher","unstructured":"Filippi, L., Bianconi, F., Schillaci, O., Spanu, A. & Palumbo, B. The role and potential of 18F-FDG PET\/CT in malignant melanoma: prognostication, monitoring response to targeted and immunotherapy, and radiomics. Diagnostics 12, 929 (2022). https:\/\/doi.org\/10.3390\/diagnostics12040929.","DOI":"10.3390\/diagnostics12040929"},{"key":"95713_CR47","doi-asserted-by":"publisher","unstructured":"Orlhac, F., Nioche, C., Klyuzhin, I., Rahmim, A. & Buvat, I. Radiomics in PET imaging: A practical fuide for newcomers. PET Clin. 16, 597\u2013612 (2021). https:\/\/doi.org\/10.1016\/j.cpet.2021.06.007.","DOI":"10.1016\/j.cpet.2021.06.007"},{"key":"95713_CR48","doi-asserted-by":"publisher","unstructured":"Im, H. J., Bradshaw, T., Solaiyappan, M. & Cho, S. Y. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nucl. Med. Mol. Imaging  52, 5\u201315 (2018). https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","DOI":"10.1007\/s13139-017-0493-6"},{"key":"95713_CR49","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","volume":"22","author":"CN Burggraaff","year":"2020","unstructured":"Burggraaff, C. N. et al. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol. Imaging Biol. 22, 1102\u20131110 (2020).","journal-title":"Mol. Imaging Biol."},{"key":"95713_CR50","doi-asserted-by":"publisher","unstructured":"Santos, D. F. et al. Whole-body tumor burden in PET\/CT expert review. Clin. Transl. Imaging 11, 5\u201322 (2023). https:\/\/doi.org\/10.1007\/s40336-022-00517-5.","DOI":"10.1007\/s40336-022-00517-5"},{"key":"95713_CR51","doi-asserted-by":"publisher","unstructured":"Dirks, I., Keyaerts, M., Dirven, I., Neyns, B. & Vandemeulebroucke, J. Development and validation of a predictive model for metastatic melanoma patients treated with pembrolizumab based on automated analysis of Whole-Body [18F]FDG PET\/CT imaging and clinical features. Cancers (Basel) 15(16), 4083 (2023). https:\/\/doi.org\/10.3390\/cancers15164083.","DOI":"10.3390\/cancers15164083"},{"key":"95713_CR52","doi-asserted-by":"crossref","unstructured":"K\u00fcstner, T. et al. Development of a hybrid-imaging-based prognostic index for metastasized-melanoma patients in whole-body 18F-FDG PET\/CT and PET\/MRI data. Diagnostics 12, 2102 (2022).","DOI":"10.3390\/diagnostics12092102"},{"key":"95713_CR53","first-page":"76","volume":"102","author":"D Angelova-Toshkina","year":"2024","unstructured":"Angelova-Toshkina, D., Weide, B., Tietze, L. F., Hebst, M. & Tietze, J. K. Correlation of baseline tumor burden with clinical outcome in melanoma patients treated with ipilimumab. Oncol. (Switzerland). 102, 76\u201384 (2024).","journal-title":"Oncol. (Switzerland)"},{"key":"95713_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 - Update and clarification: from the RECIST committee. Eur. J. Cancer. 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"95713_CR55","doi-asserted-by":"publisher","unstructured":"Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint Inhibition. J. Immunother. Cancer 8, e000842 (2020). https:\/\/doi.org\/10.1136\/jitc-2020-000842.","DOI":"10.1136\/jitc-2020-000842"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95713-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95713-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:15:22Z","timestamp":1751393722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95713-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95713"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95713-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21570"}}